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Abstract
Background: The presence of the apolipoprotein E (APOE) ε4 allele is a major risk factor for the
development of Alzheimer's disease (AD), and has been associated with metabolic brain changes several
years before the onset of typical AD symptoms. Functional MRI (fMRI) is a brain imaging technique that
has been used to demonstrate hippocampal activation during measurement of episodic encoding, but the
effect of the ε4 allele on hippocampal activation has not been firmly established.
Methods: The present study examined the effects of APOE genotype on brain activation patterns in the
medial temporal lobe (MTL) during an episodic encoding task using a well-characterized novel item versus
familiar item contrast in cognitively normal, middle-aged (mean = 54 years) individuals who had at least
one parent with AD.
Results: We found that ε3/4 heterozygotes displayed reduced activation in the hippocampus and MTL
compared to ε3/3 homozygotes. There were no significant differences between the groups in age,
education or neuropsychological functioning, suggesting that the altered brain activation seen in ε3/4
heterozygotes was not associated with impaired cognitive function. We also found that participants' ability
to encode information on a neuropsychological measure of learning was associated with greater activation
in the anterior MTL in the ε3/3 homozygotes, but not in the ε3/4 heterozygotes.
Conclusion: Together with previous studies reporting reduced glucose metabolism and AD-related
neuropathology, this study provides convergent validity for the idea that the MTL exhibits functional
decline associated with the APOE ε4 allele. Importantly, these changes were detected in the absence of
meaningful neuropsychological differences between the groups. A focus of ongoing work in this laboratory
is to determine if these findings are predictive of subsequent cognitive decline.
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Background
Family history of dementia and the apolipoprotein E
(APOE) genotype are significant risk factors for the devel-
opment of Alzheimer's disease (AD). The APOE gene,
found on chromosome 19, has three allele variants (i.e.,
ε2, ε3 and ε4) and six possible genotypes, with the ε3/3
genotype being most prevalent in the general population
(but see [1,2]). The presence of the ε4 allele significantly
increases the risk and reduces the age of onset in people
with the late-onset form of AD, the most common form of
this disorder [1,3,4]. Previous studies have reported esti-
mated cumulative lifetime risk percentages based on
APOE genotype in individuals with a family-history of AD
to be 30%, 46% and 61% for ε3/3 homozygotes, ε3/4 het-
erozygotes and ε4/4 homozygotes, respectively [5].
Impairment in the encoding and retrieval of episodic
memories, presumably caused by neurodegeneration of
the hippocampus and other medial temporal lobe (MTL)
structures [6,7], is one of the earliest symptoms in AD [8].
Recent evidence suggests that healthy ε4 carriers (mean
age = 56 years) with a family history of AD show a greater
longitudinal, age-related episodic memory decline than
non-carriers [9-11]. Furthermore, some structural MRI
studies have found reduced hippocampal volume in older
cognitively normal ε4 carriers [12-16] (but see [17-19]).
Taken together, these results suggest that there may be an
age-related phenotype for ε4 carriers involving cognitive
decline and brain atrophy prior to the onset of AD. An
important question is how early these changes occur and
whether they can be detected in vivo using existing func-
tional imaging methods.
The use of neuropsychological measures and brain imag-
ing to examine cognitively normal individuals with AD
risk factors such as family history or APOE genotype could
potentially yield valuable information about preclinical
alterations in neural function that precede the sympto-
matic stages of AD. Functional MRI (fMRI) is a non-inva-
sive brain imaging technique that has been used
successfully to demonstrate hippocampal and MTL activa-
tion during several tasks thought to reflect aspects of epi-
sodic memory [20-25]. The few studies that have
examined brain activation differences between ε4 carriers
and non-carriers have reported inconsistent findings on
measures of episodic memory.
One episodic encoding paradigm that has been used to
demonstrate robust hippocampal activation is novelty
detection, in which individuals discriminate between
events that were previously learned from events that are
novel [26-31] (see [32,33] for reviews). Tulving and Kroll
[34] have suggested that episodic encoding processes are
more evident during the processing of novel information
versus previously learned (or familiar) information.
Therefore, novelty detection appears to be an important
cognitive process involved in MTL-dependent episodic
memory formation. Novel/familiar discrimination para-
digms might therefore yield valuable information about
functional changes in the MTL that precede overt changes
in cognitive function in individuals at risk of AD.
The purpose of the present study was to use fMRI to test
the hypothesis that cognitively normal ε3/4 heterozygotes
with a family history of AD would display reduced activa-
tion in the hippocampus during a novel picture-encoding
paradigm. We also used voxel-based morphometry (VBM)
of T1 weighted images to determine whether any observed
differences in fMRI activation between the groups were
the result of differences in modulated GM volume. In
addition, we compared hippocampal activation against a
neuropsychological measure of episodic learning ability.
Because prior research has shown that brain changes pre-
cede cognitive changes in this population, and because
carriers of the ε4 allele may have altered hippocampal
function, we hypothesized that there would be less sys-
tematic shared variance, disrupting the normal relation-
ship between MTL activation and neuropsychological
status in the ε3/4 heterozygotes as compared to ε3/3
homozygotes.
Methods
Subjects
Subjects who enrolled in this fMRI study were grouped by
APOE genotype. The statistical analyses included 23 ε3/4
heterozygotes and 17 ε3/3 homozygotes. All participants
in the study were recruited from the Wisconsin Registry
for Alzheimer's Prevention (WRAP) [35], a longitudinal
study designed to identify and evaluate factors that may
delay or prevent the onset of AD. This cohort includes cog-
nitively normal adult subjects (total N > 350 participants
at the time of enrollment) between the ages of 40 and 65
with at least one biological parent who was diagnosed
with AD by physicians affiliated with the Memory Clinics
at the University of Wisconsin – Madison. The initial clin-
ical diagnosis of AD in the parent was confirmed using
published DSM-IV and NINDS-ADRDA criteria by a diag-
nostic consensus panel of experienced physicians and
neuropsychologists. The adult children of these AD
patients were then approached to participate in the WRAP
study. The self-reported mean age at onset of memory
problems in the parent diagnosed with AD was reported
by the children to be 73 years old (range = 55 – 89 years).
All subjects in the WRAP underwent baseline medical lab-
oratory tests, which included measurements of total non-
fasting blood cholesterol, blood pressure, homocysteine,
hemoglobin and hematocrit levels, and APOE genotyp-
ing. All participants also received detailed neuropsycho-
logical evaluations and baseline medical screening thatBMC Medicine 2006, 4:1 http://www.biomedcentral.com/1741-7015/4/1
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included documentation of current medication usage. An
important characteristic of this cohort is that 46% have at
least one copy of the ε4 allele [35], compared to approxi-
mately 15% in the general population [2,36]. The battery
of neuropsychological tests included the following:
Wechsler Abbreviated Scale of Intelligence (WASI) verbal
and performance IQ indexes [37], Wechsler Adult Intelli-
gence Scale-III (WAIS-III) working memory index [38],
the Controlled Oral Word Association Test (COWAT)
[39], Rey Auditory Verbal Learning Test (RAVLT) [40],
Boston Naming Test (BNT) [41], Trail Making Test A and
B [40,42], and the Center for Epidemiological Studies
Depression Inventory (CES-D) [43].
WRAP subjects were invited to participate in this fMRI
study by direct mailings and newsletters. Subjects express-
ing interest in participating were contacted by phone and
screened to determine if they met study eligibility require-
ments. The inclusion criteria consisted of the following:
no current diagnosis of major psychiatric disease or other
major medical conditions (e.g. diabetes, myocardial inf-
arction or recent history of cancer), intact cognitive func-
tions, and MRI scanner compatibility. Of the subjects
included in this study, 55% had elevated (> 200 mg/dl)
non-fasting total blood cholesterol (10 subjects in the ε3/
3 group and 12 in the ε3/4 group) and 23% had elevated
(> 140 mmHg) systolic blood pressure (5 subjects in the
ε3/3 group and 4 in the ε3/4 group). There were no sub-
jects in either groupwith high levels of homocysteine (>
14 µmol/l). Several participants were also taking a variety
of medications, 4 subjects were using cholesterol-lower-
ing medications (2 in the ε3/3 group and 2 in the ε3/4
group), 8 female subjects were current users of estrogen
replacement therapy (5 in the ε3/4 group and 3 in the ε3/
3 group), and 6 subjects were using selective serotonin
reuptake inhibitors (5 in the ε3/4 group and 1 in the ε3/3
group).
Subjects included in the overall statistical analysis were
required to have useable imaging data (movement in the
x, y and z planes < 3 mm) and at least 90% accuracy on
the fMRI memory task. We restricted our analyses to sub-
jects with a homozygous ε3/3 or heterozygous ε3/4 APOE
genotype to reduce the potential genetic variability in
brain activation patterns, and because there was an insuf-
ficient number of individuals with other APOE genotypes
(e.g. ε4/4 homozygotes or ε2/3 heterozygotes) to make
meaningful inferencesregarding other APOE genotypes.
The data from 6 additional subjects (3 ε3/3 homozygotes
and 3 ε3/4 heterozygotes) were excluded from the overall
statistical analyses: 1 subject for excessive motion during
scanning, 1 subject for scanner error, 3 subjects who did
not achieve 90% accuracy on the fMRI task, and 1 subject
who had a previously undiagnosed tumor. The final
number of subjects included in the statistical analysis was
40 (23 ε3/4 heterozygotes and 17 ε3/3 homozygotes).
Athena Diagnostics (Worchester, MA) conducted APOE
genotyping for all subjects using their patented proce-
dures.
fMRI task
Blood oxygen level dependent (BOLD) signal was
detected using a variant of a well-known fMRI paradigm
in which participants distinguished between novel and
previously learned items. This paradigm is well-suited to
examining potential differences in hippocampal activa-
tion based on APOE genotype because several previous
PET and fMRI studies have demonstrated robust hippoc-
ampal activation for novel relative to familiar contrasts.
The task consisted of serial presentations of line drawings
obtained from the Snodgrass and Vanderwart [44] set that
were matched for complexity and frequency. The previ-
ously learned pictures were presented in a training session
45 minutes prior to the task, and again during scanner
setup 15 minutes prior to the task. The items were pre-
sented repeatedly in pseudorandom fashion for 15 expo-
sures in each of the two training trials for a total of 30
exposures to each item. The participants were instructed
to view the pictures and try to remember them.
During the fMRI test session, pictures were presented con-
tinuously at 3 s intervals for the entire experiment. For
each picture, the participant decided whether the picture
Activation Maps for fMRI task Figure 1
Activation Maps for fMRI task. Statistical parametric 
maps of the single-group analyses for ε3/3 homozygotes 
(panel A) and ε3/4 heterozygotes (panel B), and for regions 
where the ε3/3 homozygotes activated to a greater extent 
than the ε3/4 heterozygotes (panel C). The left side of each 
coronal section represents the left hemisphere. The dark-
shaded area represents the MTL region to which the statisti-
cal analyses were confined. The lighter-shaded areasrepre-
sent regions outside of the MTL mask.BMC Medicine 2006, 4:1 http://www.biomedcentral.com/1741-7015/4/1
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was previously learned or novel. Each picture was pre-
sented for 2800 ms with a 200 ms interstimulus interval.
The novel pictures (condition 1) were intermixed with the
presentation of previously learned pictures (condition 2)
using a variable-length block (boxcar) paradigm. There
were no periods of rest or fixation during the entire test
session. Epoch length was variable, but appropriately bal-
anced between conditions and ranged from single events
to 5 consecutive items. The order of condition presenta-
tion and length were pseudorandom. Variable-length
epochs rather than a fully event-related approach were
used to reduce the condition predictability while main-
taining some of the statistical power of the boxcar para-
digm [45,46]. Two alternate forms of the task were
presented (order counterbalanced), using the same previ-
ously learned items but different novel items. The dura-
tion of the entire task was 9 minutes and 24 seconds.
Responses to the novel and previously learned pictures
were made with a two-button response device held in the
right hand. The index finger was used to identify previ-
ously learned pictures, whereas the middle finger was
used to identify novel pictures. As in previous studies [see
also [31]], we referred to encoding as the contrast of novel
relative to familiar pictures.
Imaging procedures
A GE 3.0 Tesla MRI scanner outfitted with an MR-compat-
ible button-box and high-resolution goggles set at 800 ×
600 (Resonance Technology; Northridge, CA) were used
for fMRI imaging and stimulus presentation. Foam pad-
ding was placed around the head to reduce head motion.
The software Presentation http://www.neuro-bs.com was
used to deliver visual stimuli and record responses in pre-
cise synchrony with slice acquisition and stimulus deliv-
ery. A T2*-weighted gradient-echo, echo-planar image
(EPI) pulse sequence was obtained with higher order
shimming during the functional trials for each subject.
The EPI parameters included: echo time flip angle = 90°;
acquisition matrix = 64 × 64 voxels; field of view (FOV) =
240 mm; echo time (TE) = 30 ms; repetition time (TR) =
2000 ms. Thirty sagittal slices of the brain were acquired
within the TR at each time point, with a voxel resolution
of 3.75 × 3.75 × 4 mm and a 1-mm skip between slices.
Table 1: Demographic, neuropsychological and fMRI task performance data
ε3/ε3 (n = 17) ε3/ε4 (n = 23)
Age (years) 52.1 (6.8) 54.0 (5.6)
Age Range (years) 42 – 65 43 – 65
Education (years) 15.9 (2.1) 16.5 (2.6)
Gender Ratio: Female/Male 11/6 13/10
Handedness (% righthanded) 94% 96%
Homocysteine (µmol/l) 8.2 (1.8) 7.9 (1.5)
Blood Cholesterol (mg/dl) 1 215.8 (32.6) 204.9 (31.4)
Hematocrit (mL/dl) 40.0 (2.1) 40.6 (2.6)
Hemoglobin (g/dl) 13.8 (0.8) 13.9 (0.9)
Systolic Blood Pressure (mmHg) 131.5 (14.1) 132.6 (17.8)
WASI Verbal IQ 112.8 (8.6) 113.6 (10.5)
WASI Performance IQ 114.0 (8.4) 111.9 (8.5)
WAIS-III Working Memory 109.5 (14.5) 104.4 (13.5)
COWAT adjusted raw score 42.8 (10.9) 47.1 (10.0)
Boston Naming Test 56.6 (2.7) 56.6 (1.8)
RAVLT total recall trials 1–5 54.0 (5.2) 52.1 (7.5)
RAVLT short delay recall 11.6 (2.6) 11.0 (2.1)
RAVLT long delay recall 11.7 (2.3) 10.7 (2.9)
RAVLT recognition 14.1 (1.2) 14.0 (1.4)
Trail Making Test A (s) 27.1 (6.0) 27.0 (8.1)
Trail Making Test B (s) 55.4 (19.7) 67.0 (22.3)*
CES-D 4.2 (4.4) 4.1 (4.2)
Snodgrass Accuracy (%) 99.1 (1.2) 98.6 (2.2)
Snodgrass RT (sec) 0.81 (0.2) 0.89 (0.1)
Snodgrass Misses 0.3 (0.8) 0.7 (1.6)
Data are presented as mean (SD). * denotes significant differences (p < 0.05) between the groups. WASI = Wechsler Abbreviated Scale of 
Intelligence, WAIS = Wechsler Adult Intelligence Scale, COWAT = Controlled Oral Word Fluency Test, RAVLT = Rey Auditory Verbal Learning 
Test, CES-D = Center for Epidemiological Studies – Depression Inventory. See text for further discussion of test measures. 1 = total non-fasting 
Blood CholesterolBMC Medicine 2006, 4:1 http://www.biomedcentral.com/1741-7015/4/1
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Over the entire test session, a total of 141 time points were
collected. Three images acquired during the first 6 seconds
of each scanning run were discarded. Following the func-
tional scans, an axial T1-weighted inversion recovery pre-
pared volume (124 slices; 1.2 mm thick; FOV 240 mm;
matrix 256 × 256), and fast recovery fast spin echo T2
weighted anatomic images (TE 90 ms; 70 slices; 1.7 mm
thick; 0.3 mm skip; FOV 240; matrix 256 × 256) were
acquired. The images were later reviewed by a neuroradi-
ologist for the presence of brain abnormalities that might
exclude subjects from the statistical analyses. The T1
weighted images were also used for the VBM analysis.
Functional image processing
The time series images were motion-corrected to reduce
the effects of head movement during the scan session. 3 D
field maps across the brain taken co-planar with the fMRI
slices were used to correct distortions in the image files by
measuring the phase of non-EPI gradient echo images at
two echo times (7 and 10 ms). The continuous B field
map was estimated using a 3 D phase-unwrapping algo-
rithm based on Jenkinson et al. [47]. Image unwrapping
was performed using a nonlinear pixel shifting and B
splines interpolation algorithm. The images were then
normalized into standard atlas space (using the T2*
weighted template from SPM2), written out at a 2 × 2 × 2
voxel resolution, and then smoothed with an 8 mm full-
width, half-maximum Gaussian kernel.
Data analysis
Analyses of the time-series data were performed using the
General Linear Model using the Statistical Parametric
Mapping (SPM2) statistical software [48]. For each partic-
ipant, the time-series statistical model included convolu-
tion with the canonical hemodynamic response function
and a high frequency signal filtering (high pass filter = 128
seconds). Temporal autocorrelation was estimated using
the first-order autoregressive (AR1) method on suprath-
reshold voxels. This method estimates the actual autocor-
relation from the fMRI time series rather than imposing a
generic temporal smoothing filter (see [49] for further dis-
cussion).
The primary contrast used to evaluate group differences
was novel versus familiar pictures. For completeness, we
also examined group differences in activation for the
familiar versus novel contrast. All single-subject analyses
for both contrasts were computed for each participant and
entered into a random effects group analysis. Each of the
single-subject analyses was completed in the same semi-
automated fashion regardless of APOE genotype. The ran-
dom-effects group analysis and the correlational analyses
were constrained to the right and left MTL, with an ana-
tomical mask described previously by Johnson et al. [50].
The mask extended from the anterior aspect of the amy-
gdala to the posterior aspect of the tail of the hippocam-
pus, and also included the fusiform and parahippocampal
gyri (See Figure 1). All possible voxels within each hemi-
sphere of the MTL mask were considered potential
dependent variables. The mask was used to impose more
stringent hypothesis-driven restrictions on the number of
simultaneous comparisons. Uncorrected p-values were
used for this restricted region of interest (ROI) approach.
In a second step, we conducted whole brain between-
group analyses for both contrasts (p < 0.05; False Discov-
ery Rate corrected for multiple comparisons) (see [51]).
Voxel-based Morphometry processing steps
The detailed processing methodology for VBM has previ-
ously been reported in detail. Briefly, we used the opti-
mized VBM approach described by Good et al. [52] (see
also [53,54]) using SPM2. This procedure involves seg-
mentation of the images into gray matter (GM), white
matter (WM) and cerebrospinal fluid (CSF), and normal-
ization of the GM images to the GM template in standard
space. The GM images were then modulated using the
Jacobian values derived from spatial normalization and
smoothed with a 12 mm isotropic Gaussian kernel. The
smoothed GM images were then entered into a random-
effects two-sample t-test in SPM2 to examine GM volume
differences between the groups.
Table 2: Montreal Neurological Institute (MNI) Coordinates for peak activation differences (p < 0.01; uncorrected) for the random-
effects group analysis between ε3/4 heterozygotes and ε3/3 homozygotes for the functional MRI encoding contrast of novel versus 
familiar pictures. k = cluster size
Contrast Region (k) Montreal Neurological Institute (MNI) coordinates Peak t value P (uncorrected)
xy z
Novel vs. Familiar
ε3/3 > ε3/4 Right anterior entorhinal cortex (60) 22 2 -34 3.56 0.001
- Right parahippocampal gyrus 22 -8 -34 2.99 0.002
Right hippocampus (93) 30 -14 -16 3.01 0.002
- Right hippocampus 36 -24 -6 2.99 0.003BMC Medicine 2006, 4:1 http://www.biomedcentral.com/1741-7015/4/1
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Results
Neuropsychological functioning and fMRI task 
performance
The mean scores and standard deviations for the demo-
graphic and laboratory test variables and neuropsycholog-
ical test performance are presented in Table 1. Between-
group differences were examined using two-sample t-tests
with a Bonferroni-corrected alpha level set at p < 0.002
(i.e., p < 0.05 divided by 22 comparisons). There were no
significant differences between the groups in respect of
age, education, laboratory test results or fMRI task per-
formance. Both groups achieved at least 98% accuracy on
the fMRI memory task and there were no differences in
reaction times. Furthermore, there were no significant dif-
ferences between the groups in terms of neuropsycholog-
ical functioning or subjective memory complaints. The
two-sample t-tests for each neuropsychological measure
revealed no significant differences between the two
groups for any of the neuropsychological test measures at
the corrected threshold of p < 0.002. However, ε3/4 heter-
ozygotes took longer to complete Trail Making Test B than
ε3/3 homozygotes, but this finding was only significant
using an uncorrected threshold of p < 0.05, whereas no
significant differences between the groups were found for
any of the other test measures. The performances of both
groups on Trail Making Test B were within the normal
range based on age-matched normative data from Spreen
and Strauss (1998), as was performance on the rest of the
neuropsychological test battery.
A follow-up analysis that included all WRAP subjects that
were ε3/3 homozygotes (n = 154) and ε3/4 heterozygotes
(n = 142), including those who did not participate in the
fMRI study, revealed no significant difference on Trails
Making Test B or any of the other neuropsychological
measures. Therefore, the significantly slower time to com-
plete Trails B in the ε3/4 heterozygotes who participated
in the fMRI study does not appear to generalize to the
WRAP cohort overall, and does not appear to be a general
effect of the APOE ε4 allele.
Imaging results
Figure 1 depicts MTL activation for the novel versus famil-
iar contrast in the ε3/3 homozygotes and ε3/4 heterozy-
gotes separately. The ε3/3 homozygotes show a greater
level of activation for the novel versus familiar contrast in
the MTL including the hippocampus compared to the ε3/
4 heterozygotes.
The single group analyses provide a qualitative descrip-
tion of differences in MTL activation between ε3/4 heter-
ozygotes and ε3/3 homozygotes. To determine whether
there were significant differences between the groups, a
random-effects 2-group t-test (with age as a covariate) for
the novel versus familiar contrast was performed in the
MTL ROI. There was a significant main effect of APOE
genotype (x, y, z: 30, -14, -16; t = 3.01, p = 0.002, uncor-
rected) with ε3/4 heterozygotes showing less activation
for the novel versus familiar pictures contrast in the MTL
than the ε3/3 homozygotes (see Figure 1). A plot of the
mean signal change averaged over a 2 mm radius sphere
in the hippocampus depicts the group difference (x, y, z:
30, -14, -16; see Figure 2). For completeness, we extracted
mean signal change at the same location in the left hip-
pocampus, and the ε3/3 homozygotes displayed numeri-
cally but not significantly (p > 0.25) greater signal change
in the left hippocampus as well (see Figure 2). Table 2 pro-
vides statistics, locations and cluster size for all signifi-
cantly activated regions for the genotype effect. There were
no significant differences in MTL activation for the con-
trast of familiar relative to novel pictures.
The whole brain analyses for the novel vs familiar and
familiar vs novel contrasts (p < 0.05; FDR corrected for
multiple comparisons) revealed no significant differences
between the groups for either contrast. In order to exam-
ine potential compensatory activity in the cortical regions
of ε3/4 heterozygotes, we conducted a follow-up analysis
(p < 0.01, uncorrected) using a two-sample t-test in which
the analysis was constrained to include only those regions
that were active for each contrast (i.e. novel versus familiar
or familiar versus novel) collapsed across all 40 subjects
(i.e. a one-sample t-test). In addition to reduced MTL acti-
vation, the ε3/4 heterozygotes also displayed reduced acti-
vation compared to the ε3/3 homozygotes for the novel
versus familiar contrast in the right ventral temporal cor-
Graph of signal change in the MTL Figure 2
Graph of signal change in the MTL. Plot of the signal 
change (adjusted fitted responses) for ε3/3 homozygotes and 
ε3/4 heterozygotes averaged over a 2 mm radius spherical 
ROI at the local maxima in the right hippocampus (x, y, z: 30, 
-14, -16), and at the same location in the left hippocampus (x, 
y, z: -30, -14, -16). Data are presented as mean signalchange 
for each group. Error bars represent the standard error of 
the mean. * denotes significant difference between the two 
groups.BMC Medicine 2006, 4:1 http://www.biomedcentral.com/1741-7015/4/1
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tex and left parietal cortex. Importantly, the ε3/4 hetero-
zygotes did not display greater activation compared to the
ε3/3 homozygotes in any brain region even at the uncor-
rected threshold of p < 0.01. There were no differences
between the groups for the familiar versus novel contrast.
To determine whether the significantly greater MTL activa-
tion displayed by the ε3/3 homozygotes relative to the ε3/
4 heterozygotes was attributable todifferential MTL atro-
phy, we used VBM analysis [53] of the T1 weighted scans
restricted to the MTL anatomical mask in these same par-
ticipants. This analysis revealed no significant differences
in modulated GM volume between the ε3/3 homozygotes
and ε3/4 heterozygotes even at a threshold of p < 0.05,
uncorrected. The absence of differential MTL atrophy indi-
cates that the observed differences in fMRI activation were
not attributable to GM volume differences in this group of
subjects.
Relationship between RAVLT and MTL activation
We also examined whether the total number of words
learned on the RAVLT was associated with fMRI activation
in the MTL for the novel relative to previously learned pic-
tures contrast in ε3/4 heterozygotes and ε3/3 homozy-
gotes. Since RAVLT variables are highly correlated, we
chose to use total words recalled on the RAVLT because
this measure has previously been shown to be sensitive to
the preclinical detection of early AD [55]. These analyses
revealed that total words learned on the RAVLT was posi-
tively associated (see Figure 3) with increased activation
in the left anterior hippocampus (x, y, z: -28, -6, -26; r =
0.58; p < 0.01), and the left amygdala (x, y, z: -38, 4, -26;
r = 0.78; p < 0.0001) in the ε3/3 homozygotes, but was not
significantly associated with activation in the MTL in ε3/4
heterozygotes (r values = -0.26 and -0.10 for left amygdala
and hippocampus, respectively). Furthermore, the magni-
tude of the correlations was significantly different
between the two groups for both the left amygdala (p <
0.0001) and hippocampus (p = 0.01). In contrast, RAVLT
total word recall was associated with activation in the left
(x, y, z: -12, -38, 12; r = 0.65, p < 0.0001) and right (x, y, z:
4, -40, 4; r = 0.65, p < 0.0001) isthmus of the cingulate cor-
tex in ε3/4 heterozygotes.
For completeness, we also determined the association
between RAVLT total word recall and signal at the same
coordinates in the right amygdala and hippocampus.
These analyses failed to reveal a significant correlation
between RAVLT total word recall and signal change in the
right amygdala or hippocampus of the ε3/3 homozygotes
(r values = 0.03 and 0.11 for the right amygdala and hip-
pocampus, respectively) or the ε3/4 heterozygotes (r val-
ues = 0.19 and 0.11, for the right amygdala and
hippocampus, respectively).
Discussion
The present study examined the effects of APOE genotype
on brain activation patterns in the MTL during an episodic
encoding task in cognitively normal individuals with a
family history of AD who were on average 15–20 years
younger than the age at which AD symptoms typically
develop. We found that ε3/4 heterozygotes displayed
reduced fMRI activation compared to ε3/3 homozygotes
in the right hippocampus and entorhinal cortex for the
contrast of novel relative to familiar pictures. Importantly,
there were no fMRI activation differences between the
groups for the reverse contrast (i.e. familiar relative to
novel), suggesting that the reduced activation found in the
right hippocampus and MTL of ε3/4 heterozygotes was
not caused by greater fMRI activation to the previously
RAVLT versus Signal Change Figure 3
RAVLT versus Signal Change. Scatter plot of the association between total words learned on the RAVLT and signal change 
within the left amygdala (left panel) and left anterior hippocampus (right panel) for ε3/3 homozygotes (black circles, solid lines) 
and ε3/4 heterozygotes (white squares, hashed lines).BMC Medicine 2006, 4:1 http://www.biomedcentral.com/1741-7015/4/1
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learned items in the ε3/4 heterozygotes, at least when
measured relative to novel items. In subsequent whole-
brain analyses, no brain regions were found to display
greater activity in the ε3/4 heterozygotes than in the ε3/3
homozygotes for either contrast.
There were also no significant differences between the
groups in age, education or memory function, and neu-
ropsychological performance was within the normal
range for both groups. This suggests that the reduced MTL
activation to novel items (relative to familiar items) in ε3/
4 heterozygotes was not caused by impaired cognitive
function, and that the observed neurobiological changes
in MTL function precede the onset of measurable decline
in cognitive function.
We also found no evidence for differences in regional GM
volume as measured by VBM, suggesting that the observed
activation differences were not caused by reduced MTL
GM volume in our cohort of middle-aged subjects. Previ-
ous volumetric studies have reported inconsistent find-
ings regarding the effects of the ε4 allele on regional brain
volume. Reiman et al. [56] reported nonsignificant trends
towards smaller left and right hippocampal volumes in
ε4/4 homozygotes (mean age = 58 years), and smaller
hippocampal volumes were associated with reduced long-
term memory ability. Den Heijer et al. [13] found that eld-
erly ε4 carriers (mean age = 72 years) displayed signifi-
cantly greater hippocampal and amygdalar atrophy and
poorer memory ability relative to ε3/3 homozygotes. Mof-
fat et al. [15] found that older ε4 carriers (mean age = 69
years) displayed a significantly greater rate of hippocam-
pal volume loss over a 3-year follow-up period, although
ε4 carriers were also found to display mild decline in
memory ability over the same time frame. In a recent
large-scale (N = 750) VBM study, Lemaitre et al. [14]
found significantly reduced MTL (including hippocam-
pus) volume in elderly (age range 63–75 years) ε4/4
homozygotes compared to both ε3/4 heterozygotes and
non-carriers, whereas no significant differences were
found between the ε3/4 heterozygotes and the non-carri-
ers. Furthermore, these authors also found that the rela-
tive risk of cognitive impairment over a 4-year follow-up
period was substantially greater in ε4/4 homozygotes rel-
ative to both ε3/4 heterozygotes and non-carriers. Other
studies have also failed to demonstrate reduced regional
brain volume in ε4 carriers [17-19]. The results of the
present study are consistent with these findings.
Since the risk of memory impairment and AD is signifi-
cantly greater in elderly ε4 carriers relative to non-carriers
and younger ε4 carriers [57], cognitive status and age
might interact with regional changes in brain volume.
Therefore, it is quite possible that the MTL volume reduc-
tions found by previous studies in elderly populations
were caused by the inclusion of APOE ε4 carriers who
were more likely to be in the early stages of AD relative to
non-carriers. This interpretation is supported by the find-
ings of previous studies that reduced MTL volume in ε4
carriers was associated with poorer memory performance
and increased risk for AD. In any case, the results of the
present study failed to demonstrate significant differences
in regional GM volume in middle-aged APOE ε3/4 heter-
ozygotes, further supporting the notion that reduced fMRI
activation in ε3/4 heterozygotes preceded overt changes in
hippocampal volume. More studies are needed to deter-
mine the conditions under which the APOE ε4 allele
results in reduced MTL volume.
In the present study, we also found that greater encoding
ability on a neuropsychological measure of learning (i.e.
RAVLT) was positively associated with fMRI activation in
the left anterior MTL in the ε3/3 homozygotes but not in
the ε3/4 heterozygotes. This signifies that among the non-
carriers (in whom the MTL is presumably more intact) the
strength of the MTL response was closely matched with
better learning ability, whereas among the ε3/4 heterozy-
gotes this relationship was disrupted. The amygdala and
anterior hippocampus relationships found in ε3/3
homozygotes are consistent with a facilitative role for the
amygdala in processing novel episodic information [58].
There was no significant difference in the magnitude of
the correlations in the amygdala and hippocampus of the
ε3/3 homozygotes, so conclusions regarding any differen-
tial contribution of these regions to encoding ability are
limited. Future studies examining amygdala-hippocampal
connectivity during encoding, as well as psychological fac-
tors (e.g. context, affective valence) that may modulate
neural activity in these regions would be required to deter-
mine the role of the amygdala in encoding of novel visual
information in people at risk of AD. Nevertheless, this
finding does suggest that the left anterior MTL was
recruited to a greater extent in ε3/3 homozygotes, whereas
ε3/4 heterozygotes with better encodingability may have
used encoding strategies that did not actively involve the
anterior MTL. The fact that the correlation was found in
the left hemisphere in ε3/3 homozygotes is consistent
with previous studies that have reported primarily left
MTL activation for encoding of verbal material (see [59]
for review but see also [60]), suggesting that subjects with
greater activation may have used a verbal encoding strat-
egy. In contrast, previous studies in cognitively healthy
young individuals (mean age = 30) have reported correla-
tions between memory ability and right hippocampal sig-
nal change [60]. The exact reason for the divergent
findings is not known. More studies examining correla-
tions between memory ability and fMRI signal change in
the left and right hippocampus during episodic encoding
are needed to clarify these findings.BMC Medicine 2006, 4:1 http://www.biomedcentral.com/1741-7015/4/1
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To date, six studies have examined brain activation differ-
ences between ε3/3 homozygotes and ε4 carriers using
fMRI, but only two of these used an activation task that
had an episodic encoding component. In a series of stud-
ies, Smith et al. [61-63] compared fMRI activation
between a group of cognitively healthy subjects with a
high risk of AD (i.e. ε4 carriers with a family history of
AD) versus a low risk group (ε3/3 homozygotes with no
family history of AD) during letter fluency and object
naming tasks relative to a low-level, resting baseline con-
dition (responding to a grayscale square that randomly
changed in intensity). These authors found that ε4 carriers
displayed increased activation in the left parietal region
during a letter fluency task, and reduced activation in the
inferotemporal cortex during the object-naming task.
Longitudinal follow-up of a smaller subset (N = 25) of
these participants four years later with the same object
naming task revealed a greater longitudinal decline in
fMRI activation in the inferotemporal cortex of the ε4 car-
riers compared to ε3/3 homozygotes. Since object naming
and letter fluency are generally affected after episodic
memory symptoms appear in AD [64], it may be that an
episodic memory task would be more helpful in assessing
the primary area of early pathology in AD – the MTL [6].
Bookheimer et al. [65] compared brain activation differ-
ences between cognitively normal ε4 carriers and ε3/3
homozygotes (age range: 47–82 years) using a paired-
associate task as a probe of episodic memory. In their task,
subjects were to encode seven unrelated word pairs over
six learning trials, in which each learning trial was fol-
lowed by 30-second periods of rest. The encoding phase
was followed by six recall trials in which subjects heard
the first word of each pair and were asked to recall the sec-
ond word silently. The major contrast used to examine
group differences was encoding + recall relative to the rest-
ing baseline. Whole-brain analysis revealed greater activa-
tion in the left prefrontal cortex, bilateral orbitofrontal,
superior temporal, and inferior and superior parietal
regions in ε4 carriers relative to the ε3/3 homozygotes for
the contrast of encoding + recall relative to rest. In follow-
up ROI analyses, these authors reported that ε4 carriers
displayed greater signal change in the left MTL as well. In
a follow-up study, Burrgren et al. [66] reported no differ-
ences between ε4 carriers and ε3/3 homozygotes during
performance of a modified digit-span (forwards) working
memory task relative to a baseline condition that was a
single digit. They hypothesized that their results reflected
a compensatory response in which ε4 carriers require
additional cognitive effort to achieve comparable per-
formance during episodic memory encoding tasks.
More recently, Bondi et al. [67] found that cognitively-
healthy, older (mean age = 76) ε4 carriers displayed
greater activation in the fusiform gyrus, parietal cortex and
frontal gyrus compared to ε3/3 homozygotes using a par-
adigm in which subjects had to discriminate novel pic-
tures from a single repeating picture. Follow-up ROI
analysis revealed that ε3/3 homozygotes displayed greater
activation in the left MTL compared to ε4 carriers, consist-
ent with the findings of the present study. In contrast, the
opposite pattern of results was found in the right MTL (i.e.
ε4 carriers displayed greater activation in the right MTL).
These authors also reported correlations between memory
ability on a word-list learning task and right and left hip-
pocampal activation during picture encoding (i.e. a posi-
tive correlation in ε3/3 homozygotes and a negative or
zero correlation in carriers of the ε4 allele) that were sim-
ilar to the correlations found in the present study. They
suggested that their results were consistent with the com-
pensatory response hypothesis described by Bookheimer
et al. [65].
The exact reason for these contradictory findings is not
knownp; however, there are several demographic and
methodological differences between our study and the
two previous fMRI studies that employed an episodic
memory task. First, our subjects were on average 10 to 23
years younger than the participants in Bookheimer et al.
[65] and Bondi et al [67], complicating comparisons
between studies. Cabeza et al. [68] found that older indi-
viduals (mean age = 70 years) displayed reduced hippoc-
ampal activation during episodic retrieval, but greater
activity in the prefrontal and parahippocampal cortices
compared to young individuals (mean age = 23 years) [see
also [69]]. Second, 60% of the subjects in Bookheimer et
al. [65] had a family-history of AD, whereas 100% of our
subjects had at least one biological parent with AD (Bondi
et al. [67] did not report the percentage of subjects in his
study with and without a family history of AD). Therefore,
differences in these demographic variables might be
responsible for the discrepant findings. Longitudinal
studies similar to Smith et al. [63] that use episodic mem-
ory tasks and employ a 2 × 2 × 2 factorial design with fam-
ily history of AD and APOE genotype as grouping
variables are needed to help clarify these findings.
Third, it is possible that the divergent findings may have
resulted from differences in the episodic memory task
employed. In the present study, we employed a relatively
straightforward novel/familiar discrimination paradigm
as the probe of episodic encoding. In contrast, Bookhe-
imer et al. [65] used a paired associate learning/recall task
that was presumably more difficult than the paradigm
used to define encoding in the present study [see [70]].
The paradigm used in the present study also differed from
the encoding task used by Bondi et al. [67]. We presented
familiar pictures in two separate trials before the fMRI
scan. In contrast, first exposure to the repeating picture
was during the fMRI task in the paradigm employed byBMC Medicine 2006, 4:1 http://www.biomedcentral.com/1741-7015/4/1
Page 10 of 14
(page number not for citation purposes)
Bondi et al. [67] and also by others e.g. [30], therefore
some reduction in hippocampal signal during the presen-
tation of the repeating novel stimulus may have occurred
(see [50]).
Fourth, it is also possible that the compensatory response
in ε4 carriers is more evident in elderly ε4 carriers rather
than middle-aged ε4 carriers. Presumably, the negative
effects of the APOE ε4 allele on hippocampal structure
and function accelerate with increasing age. It is therefore
possible that reduced hippocampal volume in elderly ε4
carriers [12-16,19,56,71] (but see [18]) might lead to the
recruitment of structures to compensate for accumulating
neuropathology in the MTL. Smith et al. [62] suggested
that increased activation in ε4 carriers might be caused by
a disruption in upstream elements of a functional net-
work, resulting in decreased input from regions that are
affected early in AD such as the MTL.
Finally, an important methodological difference between
our study and previous studies was the baseline condition
used. In the present study, we contrasted novel relative to
familiar pictures, whereas previous studies reporting
increased activation in ε4 carriers used lower level base-
line conditions. Since most fMRI designs employ a sub-
traction method (activation – baseline), the baseline task
chosen has a major effect on brain activation patterns
observed. Using rest as a baseline condition may augment
unintended effects in the experimental task such as lan-
guage or sensorimotor processes, and increase inter-sub-
ject variability in brain activation during the baseline
condition since there is less control over the mental state
of the subject (i.e. what is the subject thinking about dur-
ing the resting condition?).
To address this issue, Stark and Squire [72] designed an
elegant study to examine the effects of several different
baseline conditions including resting fixation on MTL
fMRI activation during presentation of novel and familiar
pictures. These authors found that MTL activation to
novel and familiar pictures was significantly greater when
an active task was used as a baseline (in their case, an odd/
even number comparison task) than when passive rest
was used as the baseline. In fact, several MTL regions were
found to display increased activation during rest relative
to familiar or novel pictures. In contrast, when the active
baseline task was used, both novel and familiar pictures
were associated with significant bilateral activity through-
out much of the MTL. These authors suggested that using
rest as the baseline condition may reduce, eliminate or
even reverse the sign of activity during a cognitive task. At
the very least, the lack of control over the mental state of
subjects during the resting state makes it not ideal to serve
as a baseline condition for comparison to cognitive tasks.
More recent evidence suggests that the hippocampus is
coactive during the resting state with several cortical struc-
tures including precuneus and posterior cingulate cortex
[73], and this resting state activation is disrupted in indi-
viduals with MCI and AD [74,75]. These new data make
the previous findings of increased task-related activation
relative to low-level baseline conditions in ε4 carriers
more difficult to interpret, and argue against the use of
resting baseline conditions in fMRI studies targeting these
brain regions, especially in individuals with AD or at risk
for AD.
Several positron emission tomography (PET) imaging
studies have also reported reductions in resting state cere-
bral metabolic rate of glucose (CMRgl) in the MTL and
cortical regions of AD patients and cognitively normal ε4
carriers between the ages of 20 and 65 years [76-82], sug-
gesting different baseline neural activity in individuals at
risk for AD. Reduced cerebral glucose utilization has also
been shown to inhibit the induction of synaptic plasticity
in the hippocampus of rats [83] and impair learning and
memory on hippocampus-dependent tasks [84]. Prior
research has demonstrated that CMRgl is coupled to
regional cerebral blood flow (rCBF) [85,86], and both
CMRgl [87] and rCBF [88,89] are coupled to the neural
response. The current finding of reduced hippocampal
BOLD signal during episodic encoding in ε3/4 heterozy-
gotes is consistent with these studies, supporting the idea
that reduced glucose metabolism would lead to reduced
neuronal activation in the MTL during encoding. More
research is needed to determine the relationship between
reduced resting levels of CMRgl in ε4 carriers and task-
related changes in the fMRI BOLD signal.
Reduced hippocampal activation in ε3/4 heterozygotes is
consistent with several previous fMRI studies of memory
encoding in patients with AD and MCI. For example, AD
patients display reduced hippocampal activation com-
pared to elderly controls during memory encoding
[90,91], whereas no differences were found in the motor
cortex during a sensorimotor task [90]. Machulda et al.
[90] also reported similar findings in MCI patients [see
also [92]]. Johnson et al. [50] found that elderly normal
subjects displayed a hippocampal adaptation response
(i.e. reduction in signal intensity) to repeating unfamiliar
faces that was not displayed by age-matched patients with
MCI. Taken together, these prior results indicate that MTL
activation is reduced in AD and MCI patients with objec-
tive memory impairment relative to elderly, cognitively
normal controls.
In a recent study, Dickerson et al. [93] examined differ-
ences in the extent of brain activation (i.e. number of con-
tiguous as well as non-contiguous voxels), but not the
magnitude of activation, during episodic encoding in ADBMC Medicine 2006, 4:1 http://www.biomedcentral.com/1741-7015/4/1
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patients and elderly individuals with and without subjec-
tive memory complaints who did not meet the clinical cri-
terion for MCI [94]. These authors manually traced
bilateral ROIs of the hippocampus and entorhinal cortex
from each participant's structural MRI. They found that
individuals with memory complaints displayed increased
extent of activation in each of the four ROIs relative to age-
matched subjects with no memory complaints. AD
patients were found to display significantly less extensive
activation relative to both groups. Furthermore, APOE ε4
carriers were found to display a greater extent of activation
relative to non-carriers when collapsed across the memory
complaints factor.
Dickerson et al. [93] suggested that increased extent of
MTL activation early in the course of prodromal AD was
followed by a subsequent decrease in the extent of activa-
tion as the disease progresses. An important caveat to
these findings is that the individuals with memory com-
plaints had significantly greater education and total word
recall on a word-list learning task relative to individuals
without memory complaints. Therefore, increased extent
of activation may have been related to the paradoxically
better encoding ability in individuals with memory com-
plaints. This interpretation is supported by the finding of
the present study that total word recall on the RAVLT was
associated with increased magnitude of activation during
episodic encoding, at least in the ε3/3 homozygotes. Pre-
vious studies have also reported similar findings
[60,95,96], suggesting that individuals with better epi-
sodic memory ability display greater fMRI activation in
the MTL during episodic encoding tasks.
Reduced neural function in the MTL of asymptomatic ε4
carriers may also lead to a greater age-related decline in
episodic memory over time. Several studies have reported
that older ε4 carriers display significantly greater longitu-
dinal age-related decline in episodic memory functions
than non-carriers [9-11,97,98]. For example, Caselli et al.
[97] reported that cognitively normal ε4 carriers (mean
age = 60 years) displayed significantly greater longitudinal
decline during a three-year follow-up period for total
word recall on the RAVLT and delayed recall of complex
figures. Our findings that hippocampal activation during
a novel-picture encoding task is reduced in ε3/4 heterozy-
gotes, and that memory encoding ability is positively
associated with anterior MTL activation in ε3/3 homozy-
gotes but not ε3/4 heterozygotes, are consistent with pre-
vious findings that MTL-dependent memory processes
decline at a greater rate in individuals who are ε4 carriers
and have a family history of AD. These results leave open
the possibility that ε4 carriers recruit other brain regions
and/or rely on other compensatory psychological proc-
esses (e.g. verbal rehearsal of visual information) during
encoding to compensate for early pathological changes in
MTL structure and function [65,67].
Studies in transgenic mice expressing a human form of the
APOE ε4 allele also support the negative effects of the ε4
allele on hippocampal function. For example, the pres-
ence of the APOE ε4 allele increases the production of β-
amyloid (the main constituent of the senile plaques in
AD) in cultured hippocampal neurons [99], reduces syn-
aptic plasticity in the hippocampus [100], promotes β-
amyloid induced blockade of plasticity in the hippocam-
pus [101] and impairs hippocampus-dependent spatial
memory [102,103]. Our results are consistent with these
findings as well.
This study has several limitations. We did not include a
low-level baseline condition (for the reasons discussed
above), limiting our ability to compare and contrast our
results directly to previous fMRI studies of APOE geno-
type. Furthermore, the findings of fMRI activation differ-
ences associated with APOE genotype were restricted to
ε3/3 homozygotes and ε3/4 heterozygotes with a parental
history of AD. Therefore, our results only generalize to
individuals with these APOE genotypes and a family his-
tory of AD. More studies are needed to determine the
effects of other APOE genotypes (e.g. ε4/4, ε2/3) and fam-
ily history of AD on brain activation during memory
encoding. Third, we also did not include a post-scan rec-
ognition memory test to determine if the novel pictures
were encoded into memory. While conclusions regarding
APOE genotype differences in encoding related processes
cannot be made directly from this study, they can be
inferred on the basis that novel information is more likely
to be encoded than familiar information (see also [31]).
Fourth, several of the subjects in this study had elevated
total blood cholesterol and/or high blood pressure.
Importantly, there were no group differences in the per-
centage of subjects with these conditions, and these per-
centages were also no greater than observed prevalence
rates in the general US population. Fifth, several subjects
in each group were current users of medications that influ-
ence brain function and may affect the hemodynamic
BOLD response. More studies are needed to determine the
effects of these drugs and/or medical conditions on the
fMRI signal. Finally, the subjects in this study were pre-
dominantly Caucasian, highly educated and female. Addi-
tional studies are needed to determine whether our
findings can be confirmed in subjects with other demo-
graphic characteristics. Despite these limitations, the
results of the present study provide converging evidence
for the idea that the MTL displays functional decline asso-
ciated with the APOE ε4 allele in individuals with a family
history of AD.BMC Medicine 2006, 4:1 http://www.biomedcentral.com/1741-7015/4/1
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If compromised MTL function continues to be observed in
healthy ε4 carriers, this group of subjects may represent a
good study population for novel treatments designed to
delay the onset of or to prevent AD. More studies are
needed to clarify inconsistent findings and to determine
the reliability, validity and clinical utility of hippocampal
activation paradigms for the early detection of AD.
Although the results of the present study indicate cross-
sectional differences in MTL activation based on APOE
genotype, future studies employing longitudinal designs
will be required to determine whether or not differences
in MTL activation in individuals at genetic risk for AD can
be used to improve the detection of incipient AD.
Conclusion
This study found that APOE ε3/4 heterozygotes with a
family-history of AD displayed reduced activation com-
pared to ε3/3 homozygotes in the MTL during a novel pic-
ture-encoding task. Importantly, these changes occurred
in the absence of cognitive differences between the
groups. We also found that greater encoding ability on a
neuropsychological measure of learning (i.e. RAVLT) was
positively associated with fMRI activation in the left ante-
rior MTL in the ε3/3 homozygotes but not in the ε3/4 het-
erozygotes. Together with previous studies reporting
reduced glucose metabolism and AD-related neuropa-
thology, this study provides convergent validity for the
idea that the MTL exhibits functional decline associated
with the APOE ε4 allele.
Competing interests
The author(s) declare that they have no competing inter-
ests.
Authors' contributions
MAT and TWS carried out the statistical analysis, drafted
the manuscript and assisted in the acquisition of data.
MLR, BMT and SA assisted in data acquisition and drafting
of the manuscript. MAS and BPH assisted in data acquisi-
tion, interpreting the results and drafting the manuscript.
SCJ drafted the manuscript, conceived of the study con-
cept and design, assisted in the statistical analysis and
interpretation of the results. All authors read and
approved the final manuscript.
Acknowledgements
This study was supported in part by AG021155 (SCJ). The assistance of Jus-
tin Dunker, Michael Ward, Andrew Alexander, Cynthia Carlsson, Michael 
Anderle and Ron Fisher is greatly appreciated. We would like to thank 
Mark Bondi, Lars Nyberg and Matthias Riepe for helpful comments on ear-
lier versions of this manuscript. We especially thank the WRAP participants 
of this study.
References
1. Farrer LA, Cupples LA, Haines JL, Hyman B, Kukull WA, Mayeux R,
Myers RH, Pericak-Vance MA, Risch N, van Duijn CM: Effects of
age, sex, and ethnicity on the association between apolipo-
protein E genotype and Alzheimer disease. A meta-analysis.
APOE and Alzheimer Disease Meta Analysis Consortium.
JAMA 1997, 278:1349-1356.
2. Cupples LA, Farrer LA, Sadovnick AD, Relkin N, Whitehouse P,
Green RC: Estimating risk curves for first-degree relatives of
patients with Alzheimer's disease: the REVEAL study.  Genet
Med 2004, 6:192-196.
3. Corder EH, Saunders AM, Strittmatter WJ, Schmechel DE, Gaskell
PC, Small GW, Roses AD, Haines JL, Pericak-Vance MA: Gene dose
of apolipoprotein E type 4 allele and the risk of Alzheimer's
disease in late onset families.  Science 1993, 261:921-923.
4. Duara R, Barker WW, Lopez-Alberola R, Loewenstein DA, Grau LB,
Gilchrist D, Sevush S, St George-Hyslop S: Alzheimer's disease:
interaction of apolipoprotein E genotype, family history of
dementia, gender, education, ethnicity, and age of onset.
Neurology 1996, 46:1575-1579.
5. Martinez M, Campion D, Brice A, Hannequin D, Dubois B, Didierjean
O, Michon A, Thomas-Anterion C, Puel M, Frebourg T, Agid Y, Cler-
get-Darpoux F: Apolipoprotein E epsilon4 allele and familial
aggregation of Alzheimer disease.  Arch Neurol 1998,
55:810-816.
6. Braak H, Braak E, Bohl J: Staging of Alzheimer-related cortical
destruction.  Eur Neurol 1993, 33:403-408.
7. Jack CR Jr, Petersen RC, Xu YC, O'Brien PC, Smith GE, Ivnik RJ,
Boeve BF, Waring SC, Tangalos EG, Kokmen E: Prediction of AD
with MRI-based hippocampal volume in mild cognitive
impairment.  Neurology 1999, 52:1397-1403.
8. Hyman BT, Arriagada PV, van Hoesen GW, Damasio AR: Memory
impairment in Alzheimer's Disease: An anatomical perspec-
tive.  In Neuropsychology of Alzheimer's disease and other dementias 1st
edition. Edited by: Parks RW, Zec RF, Wilson RS. New York: Oxford
University Press; 1993:138-150. 
9. Baxter LC, Caselli RJ, Johnson SC, Reiman E, Osborne D: Apolipo-
protein E epsilon 4 affects new learning in cognitively normal
individuals at risk for Alzheimer's disease.  Neurobiol Aging 2003,
24:947-952.
10. Caselli RJ, Graff-Radford NR, Reiman EM, Weaver A, Osborne D,
Lucas J, Uecker A, Thibodeau SN: Preclinical memory decline in
cognitively normal apolipoprotein E-epsilon4 homozygotes.
Neurology 1999, 53:201-207.
11. Mayeux R, Small SA, Tang M, Tycko B, Stern Y: Memory perform-
ance in healthy elderly without Alzheimer's disease: effects
of time and apolipoprotein-E.  Neurobiol Aging 2001, 22:683-689.
12. Cohen RM, Small C, Lalonde F, Friz J, Sunderland T: Effect of apol-
ipoprotein E genotype on hippocampal volume loss in aging
healthy women.  Neurology 2001, 57:2223-2228.
13. den Heijer T, Oudkerk M, Launer LJ, van Duijn CM, Hofman A,
Breteler MM: Hippocampal, amygdalar, and global brain atro-
phy in different apolipoprotein E genotypes.  Neurology 2002,
59:746-748.
14. Lemaitre H, Crivello F, Dufouil C, Grassiot B, Tzourio C, Alperovitch
A, Mazoyer B: No epsilon4 gene dose effect on hippocampal
atrophy in a large MRI database of healthy elderly subjects.
Neuroimage 2005, 24:1205-1213.
15. Moffat SD, Szekely CA, Zonderman AB, Kabani NJ, Resnick SM: Lon-
gitudinal change in hippocampal volume as a function of
apolipoprotein E genotype.  Neurology 2000, 55:134-136.
16. Plassman BL, Welsh-Bohmer KA, Bigler ED, Johnson SC, Anderson
CV, Helms MJ, Saunders AM, Breitner JC: Apolipoprotein E epsi-
lon 4 allele and hippocampal volume in twins with normal
cognition.  Neurology 1997, 48:985-989.
17. Bigler ED, Tate DF, Miller MJ, Rice SA, Hessel CD, Earl HD, Tschanz
JT, Plassman B, Welsh-Bohmer KA: Dementia, asymmetry of
temporal lobe structures, and apolipoprotein E genotype:
relationships to cerebral atrophy and neuropsychological
impairment.  J Int Neuropsychol Soc 2002, 8:925-933.
18. Jernigan TL, Archibald SL, Fennema-Notestine C, Gamst AC, Stout
JC, Bonner J, Hesselink JR: Effects of age on tissues and regions
of the cerebrum and cerebellum.  Neurobiol Aging 2001,
22:581-594.
19. Schmidt H, Schmidt R, Fazekas F, Semmler J, Kapeller P, Reinhart B,
Kostner GM: Apolipoprotein E e4 allele in the normal elderly:
neuropsychologic and brain MRI correlates.  Clin Genet 1996,
50:293-299.BMC Medicine 2006, 4:1 http://www.biomedcentral.com/1741-7015/4/1
Page 13 of 14
(page number not for citation purposes)
20. Cabeza R, Dolcos F, Graham R, Nyberg L: Similarities and differ-
ences in the neural correlates of episodic memory retrieval
and working memory.  Neuroimage 2002, 16:317-330.
21. Cabeza R, Prince SE, Daselaar SM, Greenberg DL, Budde M, Dolcos
F, LaBar KS, Rubin DC: Brain activity during episodic retrieval
of autobiographical and laboratory events: an fMRI study
using a novel photo paradigm.  J Cogn Neurosci 2004,
16:1583-1594.
22. Cabeza R, Rao SM, Wagner AD, Mayer AR, Schacter DL: Can
medial temporal lobe regions distinguish true from false? An
event-related functional MRI study of veridical and illusory
recognition memory.  Proc Natl Acad Sci U S A 2001, 98:4805-4810.
23. Gron G, Bittner D, Schmitz B, Wunderlich AP, Tomczak R, Riepe
MW: Hippocampal activations during repetitive learning and
recall of geometric patterns.  Learn Mem 2001, 8:336-345.
24. Gron G, Wunderlich AP, Spitzer M, Tomczak R, Riepe MW: Brain
activation during human navigation: gender-different neural
networks as substrate of performance.  Nat Neurosci 2000,
3:404-408.
25. Nyberg L, McIntosh AR, Cabeza R, Habib R, Houle S, Tulving E: Gen-
eral and specific brain regions involved in encoding and
retrieval of events: what, where, and when.  Proc Natl Acad Sci
U S A 1996, 93:11280-11285.
26. Brewer JB, Zhao Z, Desmond JE, Glover GH, Gabrieli JD: Making
memories: brain activity that predicts how well visual expe-
rience will be remembered.  Science 1998, 281:1185-1187.
27. Grunwald T, Lehnertz K, Heinze HJ, Helmstaedter C, Elger CE: Ver-
bal novelty detection within the human hippocampus
proper.  Proc Natl Acad Sci U S A 1998, 95:3193-3197.
28. Habib R, McIntosh AR, Wheeler MA, Tulving E: Memory encoding
and hippocampally-based novelty/familiarity discrimination
networks.  Neuropsychologia 2003, 41:271-279.
29. Knight R: Contribution of human hippocampal region to nov-
elty detection.  Nature 1996, 383:256-259.
30. Stern CE, Corkin S, Gonzalez RG, Guimaraes AR, Baker JR, Jennings
PJ, Carr CA, Sugiura RM, Vedantham V, Rosen BR: The hippocam-
pal formation participates in novel picture encoding: evi-
dence from functional magnetic resonance imaging.  Proc Natl
Acad Sci U S A 1996, 93:8660-8665.
31. Tulving E, Markowitsch HJ, Craik FE, Habib R, Houle S: Novelty and
familiarity activations in PET studies of memory encoding
and retrieval.  Cereb Cortex 1996, 6:71-79.
32. Lepage M, Habib R, Tulving E: Hippocampal PET activations of
memory encoding and retrieval: the HIPER model.  Hippoc-
ampus 1998, 8:313-322.
33. Ranganath C, Rainer G: Neural mechanisms for detecting and
remembering novel events.  Nat Rev Neurosci 2003, 4:193-202.
34. Tulving E, Kroll N: Novelty assessment in the brain and long-
term memory encoding.  Psychonomic Bulletin and Review 1995,
2:387-390.
35. Sager MA, Hermann BP, La Rue A: Middle-aged Children of Per-
sons with Alzheimer's Disease: APOE Genotypes and Cogni-
tive Function in the Wisconsin Registry for Alzheimer's
Prevention.  Journal of Geriatric Psychiatry and Neurology  in press.
36. Zannis VI, Kardassis D, Zanni EE: Genetic mutations affecting
human lipoproteins, their receptors, and their enzymes.  Adv
Hum Genet 1993, 21:145-319.
37. Wechsler D: Wechsler abbreviated scale of intelligence 1st edition. San
Antonio, TX: Psychological Corporation; 1999. 
38. Wechsler D: Wechsler adult intelligence scale 3rd edition. San Antonio,
TX: The Psychological Corporation; 1997. 
39. Benton LA, Hamsher K, Sivan AB: Controlled Oral Word Association
Test. Multilingual Aphasia Examination 3rd edition. Iowa City, IA: AJA;
1994. 
40. Spreen O, Strauss E: A Compendium of Neuropsychological Tests New
York: Oxford; 1998. 
41. Goodglass H, Kaplan E: The assessment of aphasia and related disorders
2nd edition. Philadelphia: Lea & Febiger; 1987. 
42. Reitan RM, Wolfson D: The Halstead-Reitan Neuropsychological Test
Battery: Theory and clinical interpretation 2nd edition. Tucson: Neu-
ropsychology Press; 1993. 
43. Radloff LS: The CES-D scale: a self-report depression scale for
research in the general population.  Applied Psychological Meas-
urements 1977, 1:385-401.
44. Snodgrass J, Vanderwart M: A standardized set of 260 pictures:
Norms for name agreement, image agreement, familiarity,
and visual complexity.  Journal of Experimental Psychology: Human
Learning and Memory 1980, 6:174-215.
45. Moritz CH, Johnson S, Meyerand ME: Variable-length block
memory encoding paradigm demonstrates individual sub-
ject hippocampal fMRI response.  Proc Intl Soc Magn Res Med
2002, 10:.
46. Liu TT, Frank LR, Wong EC, Buxton RB: Detection power, esti-
mation efficiency, and predictability in event-related fMRI.
Neuroimage 2001, 13:759-773.
47. Jenkinson M: Fast, automated, N-dimensional phase-unwrap-
ping algorithm.  Magn Reson Med 2003, 49:193-197.
48. Friston KJ, Holmes AP, Worsley KJ, Poline JP, Frith CD, Frackowiak
RSJ: Statistical parametric maps in functional imaging: A gen-
eral linear approach.  Human Brain Mapping 1995, 2:189-210.
49. Bullmore E, Brammer M, Williams SC, Rabe-Hesketh S, Janot N,
David A, Mellers J, Howard R, Sham P: Statistical methods of esti-
mation and inference for functional MR image analysis.  Magn
Reson Med 1996, 35:261-277.
50. Johnson SC, Baxter LC, Susskind-Wilder L, Connor DJ, Sabbagh MN,
Caselli RJ: Hippocampal adaptation to face repetition in
healthy elderly and mild cognitive impairment.  Neuropsycholo-
gia 2004, 42:980-989.
51. Genovese CR, Lazar NA, Nichols T: Thresholding of statistical
maps in functional neuroimaging using the false discovery
rate.  Neuroimage 2002, 15:870-878.
52. Good CD, Johnsrude IS, Ashburner J, Henson RN, Friston KJ, Frack-
owiak RS: A voxel-based morphometric study of ageing in 465
normal adult human brains.  Neuroimage 2001, 14:21-36.
53. Ashburner J, Friston KJ: Voxel-based morphometry--the meth-
ods.  Neuroimage 2000, 11:805-821.
54. McMillan AB, Hermann BP, Johnson SC, Hansen RR, Seidenberg M,
Meyerand ME: Voxel-based morphometry of unilateral tempo-
ral lobe epilepsy reveals abnormalities in cerebral white
matter.  Neuroimage 2004, 23:167-174.
55. Albert MS, Moss MB, Tanzi R, Jones K: Preclinical prediction of
AD using neuropsychological tests.  J Int Neuropsychol Soc 2001,
7:631-639.
56. Reiman EM, Uecker A, Caselli RJ, Lewis S, Bandy D, de Leon MJ, De
Santi S, Convit A, Osborne D, Weaver A, Thibodeau SN: Hippoc-
ampal volumes in cognitively normal persons at genetic risk
for Alzheimer's disease.  Ann Neurol 1998, 44:288-291.
57. Devanand DP, Pelton GH, Zamora D, Liu X, Tabert MH, Goodkind
M, Scarmeas N, Braun I, Stern Y, Mayeux R: Predictive utility of
apolipoprotein E genotype for Alzheimer disease in outpa-
tients with mild cognitive impairment.  Arch Neurol 2005,
62:975-980.
58. Wright CI, Martis B, Schwartz CE, Shin LM, Fischer HH, McMullin K,
Rauch SL: Novelty responses and differential effects of order
in the amygdala, substantia innominata, and inferior tempo-
ral cortex.  Neuroimage 2003, 18:660-669.
59. Cabeza R, Nyberg L: Imaging cognition II: An empirical review
of 275 PET and fMRI studies.  J Cogn Neurosci 2000, 12:1-47.
60. Johnson SC, Saykin AJ, Flashman LA, McAllister TW, Sparling MB:
Brain activation on fMRI and verbal memory ability: func-
tional neuroanatomic correlates of CVLT performance.  J Int
Neuropsychol Soc 2001, 7:55-62.
61. Smith CD, Andersen AH, Kryscio RJ, Schmitt FA, Kindy MS, Blonder
LX, Avison MJ: Altered brain activation in cognitively intact
individuals at high risk for Alzheimer's disease.  Neurology
1999, 53:1391-1396.
62. Smith CD, Andersen AH, Kryscio RJ, Schmitt FA, Kindy MS, Blonder
LX, Avison MJ: Women at risk for AD show increased parietal
activation during a fluency task.  Neurology 2002, 58:1197-1202.
63. Smith CD, Kryscio RJ, Schmitt FA, Lovell MA, Blonder LX, Rayens
WS, Andersen AH: Longitudinal Functional Alterations in
Asymptomatic Women at Risk for Alzheimer's Disease.  J
Neuroimaging 2005, 15:271-277.
64. Zec RF: Neuropsychological functioning in Alzheimer's Dis-
ease.  In Neuropsychology of Alzheimer's disease and other dementias 1st
edition. Edited by: Parks RW, Zec RF, Wilson RS. New York: Oxford
University Press; 1993:3-80. 
65. Bookheimer SY, Strojwas MH, Cohen MS, Saunders AM, Pericak-
Vance MA, Mazziotta JC, Small GW: Patterns of brain activation
in people at risk for Alzheimer's disease.  N Engl J Med 2000,
343:450-456.BMC Medicine 2006, 4:1 http://www.biomedcentral.com/1741-7015/4/1
Page 14 of 14
(page number not for citation purposes)
66. Burggren AC, Small GW, Sabb FW, Bookheimer SY: Specificity of
brain activation patterns in people at genetic risk for Alzhe-
imer disease.  Am J Geriatr Psychiatry 2002, 10:44-51.
67. Bondi MW, Houston WS, Eyler LT, Brown GG: fMRI evidence of
compensatory mechanisms in older adults at genetic risk for
Alzheimer disease.  Neurology 2005, 64:501-508.
68. Cabeza R, Daselaar SM, Dolcos F, Prince SE, Budde M, Nyberg L:
Task-independent and task-specific age effects on brain
activity during working memory, visual attention and epi-
sodic retrieval.  Cereb Cortex 2004, 14:364-375.
69. Daselaar SM, Veltman DJ, Rombouts SA, Raaijmakers JG, Jonker C:
Neuroanatomical correlates of episodic encoding and
retrieval in young and elderly subjects.  Brain 2003, 126:43-56.
70. Watkins MJ, Gardiner JM: An appreciation of generate-recog-
nize theory of recall.  Journal of Verbal Learning and Verbal Behavior
1979, 18:687-704.
71. Tohgi H, Takahashi S, Kato E, Homma A, Niina R, Sasaki K, Yonezawa
H, Sasaki M: Reduced size of right hippocampus in 39- to 80-
year-old normal subjects carrying the apolipoprotein E
epsilon4 allele.  Neurosci Lett 1997, 236:21-24.
72. Stark CE, Squire LR: When zero is not zero: the problem of
ambiguous baseline conditions in fMRI.  Proc Natl Acad Sci U S A
2001, 98:12760-12766.
73. Greicius MD, Krasnow B, Reiss AL, Menon V: Functional connec-
tivity in the resting brain: a network analysis of the default
mode hypothesis.  Proc Natl Acad Sci U S A 2003, 100:253-258.
74. Greicius MD, Srivastava G, Reiss AL, Menon V: Default-mode net-
work activity distinguishes Alzheimer's disease from healthy
aging: evidence from functional MRI.  Proc Natl Acad Sci U S A
2004, 101:4637-4642.
75. Rombouts SA, Barkhof F, Goekoop R, Stam CJ, Scheltens P: Altered
resting state networks in mild cognitive impairment and
mild Alzheimer's disease: An fMRI study.  Hum Brain Mapp
2005, 26:231-239.
76. Alexander GE, Chen K, Pietrini P, Rapoport SI, Reiman EM: Longitu-
dinal PET Evaluation of Cerebral Metabolic Decline in
Dementia: A Potential Outcome Measure in Alzheimer's
Disease Treatment Studies.  Am J Psychiatry 2002, 159:738-745.
77. Reiman EM, Caselli RJ, Chen K, Alexander GE, Bandy D, Frost J:
Declining brain activity in cognitively normal apolipoprotein
E epsilon 4 heterozygotes: A foundation for using positron
emission tomography to efficiently test treatments to pre-
vent Alzheimer's disease.  Proc Natl Acad Sci U S A 2001,
98:3334-3339.
78. Reiman EM, Caselli RJ, Alexander GE, Chen K: Tracking the
decline in cerebral glucose metabolism in persons and labo-
ratory animals at genetic risk for Alzheimer's disease.  Clinical
Neuroscience Research 2001, 1:194-206.
79. Reiman EM, Caselli RJ, Yun LS, Chen K, Bandy D, Minoshima S, Thib-
odeau SN, Osborne D: Preclinical evidence of Alzheimer's dis-
ease in persons homozygous for the epsilon 4 allele for
apolipoprotein E.  N Engl J Med 1996, 334:752-758.
80. Reiman EM, Chen K, Alexander GE, Caselli RJ, Bandy D, Osborne D,
Saunders AM, Hardy J: Functional brain abnormalities in young
adults at genetic risk for late-onset Alzheimer's dementia.
Proc Natl Acad Sci U S A 2004, 101:284-289.
81. Small GW, Mazziotta JC, Collins MT, Baxter LR, Phelps ME, Mandelk-
ern MA, Kaplan A, La Rue A, Adamson CF, Chang L: Apolipopro-
tein E type 4 allele and cerebral glucose metabolism in
relatives at risk for familial Alzheimer disease.  JAMA 1995,
273:942-947.
82. Small GW, Ercoli LM, Silverman DH, Huang SC, Komo S, Bookheimer
SY, Lavretsky H, Miller K, Siddarth P, Rasgon NL, Mazziotta JC,
Saxena S, Wu HM, Mega MS, Cummings JL, Saunders AM, Pericak-
Vance MA, Roses AD, Barrio JR, Phelps ME: Cerebral metabolic
and cognitive decline in persons at genetic risk for Alzhe-
imer's disease.  Proc Natl Acad Sci U S A 2000, 97:6037-6042.
83. Izumi Y, Zorumski CF: Involvement of nitric oxide in low glu-
cose-mediated inhibition of hippocampal long-term potenti-
ation.  Synapse 1997, 25:258-262.
84. Biessels GJ, Kamal A, Ramakers GM, Urban IJ, Spruijt BM, Erkelens
DW, Gispen WH: Place learning and hippocampal synaptic
plasticity in streptozotocin-induced diabetic rats.  Diabetes
1996, 45:1259-1266.
85. Sokoloff L: Modeling metabolic processes in the brain in vivo.
Ann Neurol 1984, 15(Suppl):S1-11.
86. Sokoloff L: Metabolic probes for localization of functional
activity in the central nervous system.  Int J Neurol 1984,
18:40-48.
87. Mosconi L, De Santi S, Rusinek H, Convit A, de Leon MJ: Magnetic
resonance and PET studies in the early diagnosis of Alzhe-
imer's disease.  Expert Rev Neurother 2004, 4:831-849.
88. Logothetis NK, Wandell BA: Interpreting the BOLD signal.  Annu
Rev Physiol 2004, 66:735-769.
89. Heeger DJ, Ress D: What does fMRI tell us about neuronal
activity?  Nat Rev Neurosci 2002, 3:142-151.
90. Machulda MM, Ward HA, Borowski B, Gunter JL, Cha RH, O'Brien
PC, Petersen RC, Boeve BF, Knopman D, Tang-Wai DF, Ivnik RJ,
Smith GE, Tangalos EG, Jack CR Jr: Comparison of memory fMRI
response among normal, MCI, and Alzheimer's patients.
Neurology 2003, 61:500-506.
91. Sperling RA, Bates JF, Chua EF, Cocchiarella AJ, Rentz DM, Rosen BR,
Schacter DL, Albert MS: fMRI studies of associative encoding in
young and elderly controls and mild Alzheimer's disease.  J
Neurol Neurosurg Psychiatry 2003, 74:44-50.
92. Johnson SC, Schmitz TW, Moritz CH, Meyerand ME, Rowley HA,
Alexander AL, Hansen KW, Gleason CE, Carlsson CM, Ries ML,
Asthana S, Chen K, Reiman EM, Alexander GE: Activation of brain
regions vulnerable to Alzheimer's disease: The effect of mild
cognitive impairment.  Neurobiol Aging  in press.
93. Dickerson BC, Salat DH, Greve DN, Chua EF, Rand-Giovannetti E,
Rentz DM, Bertram L, Mullin K, Tanzi RE, Blacker D, Albert MS, Sper-
ling RA: Increased hippocampal activation in mild cognitive
impairment compared to normal aging and AD.  Neurology
2005, 65:404-411.
94. Petersen RC: Mild cognitive impairment as a diagnostic entity.
J Intern Med 2004, 256:183-194.
95. Gron G, Bittner D, Schmitz B, Wunderlich AP, Tomczak R, Riepe
MW:  Variability in memory performance in aged healthy
individuals: an fMRI study.  Neurobiol Aging 2003, 24:453-462.
96. Gron G, Riepe MW: Neural basis for the cognitive continuum
in episodic memory from health to Alzheimer disease.  Am J
Geriatr Psychiatry 2004, 12:648-652.
97. Caselli RJ, Reiman EM, Osborne D, Hentz JG, Baxter LC, Hernandez
JL, Alexander GG: Longitudinal changes in cognition and
behavior in asymptomatic carriers of the APOE e4 allele.
Neurology 2004, 62:1990-1995.
98. Dik MG, Jonker C, Bouter LM, Geerlings MI, van Kamp GJ, Deeg DJ:
APOE-epsilon4 is associated with memory decline in cogni-
tively impaired elderly.  Neurology 2000, 54:1492-1497.
99. Lahiri DK, Sambamurti K, Bennett DA: Apolipoprotein gene and
its interaction with the environmentally driven risk factors:
molecular, genetic and epidemiological studies of Alzhe-
imer's disease.  Neurobiol Aging 2004, 25:651-660.
100. Trommer BL, Shah C, Yun SH, Gamkrelidze G, Pasternak ES, Ye GL,
Sotak M, Sullivan PM, Pasternak JF, Ladu MJ: ApoE isoform affects
LTP in human targeted replacement mice.  Neuroreport 2004,
15:2655-2658.
101. Yun SH, Gamkrelidze G, Pasternak JF, LaDu M, Trommer BL: Oligo-
meric amyloid 1–42 decreases the excitability of dentate
gyrus granule cells in hippocampal slices from ApoE4-TR
mice.  Society for Neuroscience Abstract Viewer/Itinerary Planner Online
2004. Program No. 217.219
102. Raber J, Wong D, Buttini M, Orth M, Bellosta S, Pitas RE, Mahley RW,
Mucke L: Isoform-specific effects of human apolipoprotein E
on brain function revealed in ApoE knockout mice:
increased susceptibility of females.  Proc Natl Acad Sci U S A 1998,
95:10914-10919.
103. Harris FM, Brecht WJ, Xu Q, Tesseur I, Kekonius L, Wyss-Coray T,
Fish JD, Masliah E, Hopkins PC, Scearce-Levie K, Weisgraber KH,
Mucke L, Mahley RW, Huang Y: Carboxyl-terminal-truncated
apolipoprotein E4 causes Alzheimer's disease-like neurode-
generation and behavioral deficits in transgenic mice.  Proc
Natl Acad Sci U S A 2003, 100:10966-10971.
Pre-publication history
The pre-publication history for this paper can be accessed
here:
http://www.biomedcentral.com/1741-7015/4/1/prepub